Definition:Competition and Markets Authority (CMA) review
🇬🇧 Competition and Markets Authority (CMA) review is the merger-control process administered by the United Kingdom's principal competition regulator, which scrutinizes transactions — including those in the insurance and reinsurance sectors — to determine whether they may result in a substantial lessening of competition in any UK market. Since Brexit removed the UK from the EU Merger Regulation's one-stop-shop mechanism, deals involving insurers, brokers, or insurtech firms with significant UK revenue now require a separate CMA assessment even if they have already secured European Commission clearance.
⚙️ The CMA can review mergers on a voluntary or own-initiative basis; there is no mandatory notification requirement, but the authority has the power to call in transactions that meet its jurisdictional thresholds — generally where the target's UK turnover exceeds £70 million or where the merged entity would supply at least 25 percent of a particular good or service in the UK. A Phase 1 investigation lasts up to 40 working days, and if concerns are not resolved through divestiture undertakings or other remedies, the case proceeds to a Phase 2 in-depth inquiry conducted by an independent panel. For insurance transactions, the CMA examines market concentration across lines such as commercial, personal, life, and specialty segments, and it pays close attention to whether reduced competition in distribution or underwriting would lead to higher premiums or diminished choice for policyholders.
💡 The practical consequence of a separate CMA track is that global insurance mergers now face a tripartite clearance landscape: the United States ( FTC or DOJ), the EU, and the UK — each with its own market definitions, timelines, and remedial preferences. Add to that the PRA and FCA approvals required for changes of control in UK-authorized insurance entities, and the regulatory choreography becomes formidable. For cross-border deals, experienced advisors often map out a unified CMA/PRA engagement strategy to avoid conflicting remedy commitments and keep both workstreams advancing in parallel.
Related concepts: